老年人多重用药的全球患病率、趋势及剂量反应关联
多重用药随日历年份呈显著上升趋势,并与多种不良结局风险升高相关,每增加一种药物风险呈单调递增。
要点
- 全球约半数老年人存在多重用药,患病率为50.4%(95%CI:48.2%-52.7%)。
- 多重用药患病率随日历年份呈显著上升趋势。
- 每增加一种药物,死亡、急诊就诊和住院风险均单调升高。
核心结论
- 多重用药影响全球约半数老年人,且随时间稳步增加,并与多种不良健康结局风险升高相关,风险随用药负担增加而逐步上升。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane Library、Web of Science和Scopus自建库至2025年6月30日的文献,采用随机效应荟萃分析合并患病率和相对风险,并以Hoy法评估研究质量。
主要发现
- 多重用药全球合并患病率为50.4%(95%CI:48.2%-52.7%;95%预测区间:6.8%-93.5%)。
- 多重用药患病率随日历年份呈显著上升趋势。
- 与非多重用药相比,多重用药与多种不良结局风险显著升高相关。
关键数值与推荐
- 剂量反应荟萃分析显示每增加一种药物,死亡风险比为1.05(95%CI:1.03-1.06,p<.001)。
- 每增加一种药物,急诊就诊风险比为1.02(95%CI:1.02-1.03,p<.001)。
- 每增加一种药物,住院风险比为1.04(95%CI:1.02-1.07,p<.001)。
- 结局特异性阈值范围为4.55至5.46种药物,跨结局的描述性汇总约为五种药物。
临床怎么用
- 对老年患者应常规评估用药数量,关注多重用药与不良结局风险的关联。
- 处方决策时可参考约五种药物的描述性汇总阈值,结合患者具体情况评估用药负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polypharmacy is common in older adults with comorbidities. This study aims to estimate its global prevalence, temporal trends, and dose-response associations with adverse health outcomes. PubMed, Embase, The Cochrane Library, Web of Science, and Scopus were searched from inception to June 30, 2025. Random-effects meta-analyses were used to pool prevalence estimates of polypharmacy based on mixed thresholds and relative risks. Study quality was assessed using Hoy's method. Hazard ratios (HRs) from individual studies were synthesized using random-effects dose-response meta-analysis in studies that provided sufficient quantitative exposure information. A total of 545 studies, providing 565 prevalence estimates, were included, comprising 16 620 414 older adults from 56 countries worldwide. The pooled global prevalence of polypharmacy was 50.4% (95% confidence interval [CI]: 48.2%-52.7%; 95% prediction interval: 6.8%-93.5%). It demonstrated a significant increasing temporal trend in polypharmacy prevalence over calendar years. Compared with non-polypharmacy, polypharmacy was associated with a significantly higher risk of multiple adverse outcomes. Dose-response meta-analyses showed a monotonic increase in risk with each additional medication for mortality (HR: 1.05, 95% CI: 1.03-1.06, p < .001), emergency (HR: 1.02, 95% CI: 1.02-1.03, p < .001), and hospital admission (HR: 1.04, 95% CI: 1.02-1.07, p < .001). Outcome-specific thresholds ranged from 4.55 to 5.46 medications. A pooled estimate of approximately five medications was obtained as a descriptive summary across outcomes. Polypharmacy affects approximately half of older adults worldwide and has increased steadily over time. It is associated with an increased risk of multiple adverse health outcomes, with risks increasing progressively as medication burden rises.
引用
- Tian F, Chen Z, Zhang Y, et al. Global prevalence, trends, and dose-response associations of polypharmacy in older adults. J Gerontol A Biol Sci Med Sci. 2026. PMID: 42412515. doi:10.1093/gerona/glag176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。